Decreasing levels of the cdk5 activators, p25 and p35, reduces excitotoxicity in striatal neurons

Journal of Huntington's Disease

Volumn 1, Issue 1, 2012, Pages 89-96

  Park, Kevin H J ^a   Lu, Ge ^a   Fan, Jing ^b   Raymond, Lynn A ^b,c   Leavitt, Blair R ^a,c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

cdk5; excitotoxic; Huntington's disease; medium spiny neuron; neurodegeneration; NMDA; p25; quinolinic acid; striatum; YAC128

Indexed keywords

CYCLIN DEPENDENT KINASE 5; HUNTINGTIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PROTEIN P25; PROTEIN P35; QUINOLINIC ACID; CDK5R1 PROTEIN, MOUSE; N METHYLASPARTIC ACID; NEUROTOXIN; PHOSPHOTRANSFERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DEATH; CORPUS STRIATUM; ENZYME ACTIVATION; EXCITOTOXICITY; GENE DELETION; HEMIZYGOSITY; HUNTINGTON CHOREA; MOUSE; NERVE CELL PLASTICITY; NEUROPROTECTION; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; WESTERN BLOTTING; WILD TYPE; ANALYSIS OF VARIANCE; ANIMAL; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; METABOLISM; NERVE CELL; PATHOLOGY; TRANSGENIC MOUSE;

ANALYSIS OF VARIANCE; ANIMALS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; HUNTINGTON DISEASE; MICE; MICE, TRANSGENIC; N-METHYLASPARTATE; NEURONS; NEUROTOXINS; PHOSPHOTRANSFERASES;

EID: 84930189809     PISSN: 18796397     EISSN: 18796400     Source Type: Journal    
DOI: 10.3233/JHD-2012-129000     Document Type: Article

References (33)

1. Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell. 1993;72:971-83.
2. Ferrante R, Kowall N, Beal M, Richardson EJ, Bird E, Martin J. Selective sparing of a class of striatal neurons in Huntington's disease. Science. 1985;230(4725):561-3. (Pubitemid 16169813)
3. Zeron MM, Hansson O, Chen N, Wellington CL, Leavitt BR, Brundin P, et al. Increased sensitivity to N-methyl-Daspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron. 2002;33:849-60. (Pubitemid 34246352)
4. Fernandes H, Baimbridge K, Church J, Hayden M, Raymond L. Mitochondrial sensitivity and altered calcium handling underlie enhanced NMDA-induced apoptosis in YAC128 model of Huntington's disease. J Neurosci. 2007;27(50): 13614-23. (Pubitemid 350278271)
5. Vosler PS, Brennan CS, Chen J. Calpain-mediated signaling mechanisms in neuronal injury and neurodegeneration. Mol Neurobiol. 2008;38:78-100.
6. Gafni J, Ellerby LM. Calpain activation in Huntington's disease. J Neurosci. 2002;22(12):4842-9. (Pubitemid 37465599)
7. Cowan CM, Fan MMY, Fan J, Shehadeh J, Zhan LYJ, Graham RK, et al. Polyglutamine-modulated striatal calpain activity in YAC transgenic huntington disease mouse model: impact on NMDA receptor function and toxicity. J Neurosci. 2008;28(48):12725-35.
8. Lee KY, Rosales JL, Tang D,Wang JH. Interaction of cyclindependent kinase 5 (Cdk5) and neuronal Cdk5 activator in bovine brain. J Biol Chem. 1996;271(3):1538-43. (Pubitemid 26028642)
9. Tang D,Yeung J, Lee KY, Matsushita M, Matsui H, Tomizawa K, et al. An isoform of the neuronal cyclin-dependent kinase 5 (Cdk5) activator. J Biol Chem. 1995;270(45):26897-903.
10. Tsai LH, Delalle I, Caviness VS Jr, Chae T, Harlow E. p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5. Nature. 1994;371(6496):419-23. (Pubitemid 24302556)
11. Mao D, Hinds P. p35 is required for CDK5 activation in cellular senescence. J Biol Chem. 2010;285(19):14671-80.
12. Dhavan R, Tsai LH. A decade of CDK5. Nat Rev Mol Cell Biol. 2001;2(10):749-59. (Pubitemid 33679837)
13. Hisanaga S, Endo R. Regulation and role of cyclin-dependent kinase activity in neuronal survival and death. J Neurochem. 2010;115:1309-21.
14. Lopes J, Agostinho P. Cdk5: multitasking between physiological and pathological conditions. Prog Neurobiol. 2011;94(1):49-63.
15. Cheung Z, Ip N. Cdk5: A multifaceted kinase in neurodegenerative diseases. Trends Cell Biol. 2011.
16. Patrick GN, Zukerberg L, Nikolic M, de la Monte S, Dikkes P, Tsai LH. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature. 1999;402(6762):615-22. (Pubitemid 129516324)
17. Lee MS, Kwon YT, Li M, Peng J, Friedlander RM, Tsai LH. Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature. 2000;405(6784):360-4. (Pubitemid 30337070)
18. Kusakawa G, Saito T, Onuki R, Ishiguro K, Kishimoto T, Hisanaga S. Calpain-dependent proteolytic cleavage of the p35 cyclin-dependent kinase 5 activator to p25. J Biol Chem. 2000;275(22):17166-72. (Pubitemid 30398964)
19. Asada A, Yamamoto N, Gohda M, Saito T, Hayashi N, Hisanaga S. Myristoylation of p39 and p35 is a determinant of cytoplasmic or nuclear localization of active cyclin-dependent kinase 5 complexes. J Neurochem. 2008;106(3):1325-36.
20. Paoletti P, Vila I, Rife M, Lizcano JM, Alberch J, Gines S. Dopaminergic and glutamatergic signaling crosstalk in Huntington's disease neurodegeneration: the role of p25/cyclindependent kinase 5. J Neurosci. 2008;28(40):10090-101.
21. Crespo-Biel N, Camins A, Pelegri C, Vilaplana J, Pall'as M, Canudas AM. 3-Nitropropionic acid activates calpain/cdk5 pathway in rat striatum. Neurosci Lett. 2007;421:77-81. (Pubitemid 46899331)
22. Hallows JL, Chen K, DePinho RA, Vincent I. Decreased cyclin-dependent kinase 5 (cdk5) activity is accompanied by redistribution of cdk5 and cytoskeletal proteins and increased cytoskeletal protein phosphorylation in p35 null mice. J Neurosci. 2003;23(33):10633-44. (Pubitemid 37485277)
23. Fan. J, Cowan C, Zhang L, Hayden M, Raymond L. Interaction of postsynaptic density protein-95 with NMDA receptors influences excitotoxicity in the yeast artificial chromosome mouse model of Huntington's disease. J Neurosci. 2009;29(35):10928-38.
24. Park KHJ, Hallows JL, Chakrabarty P, Davies P, Vincent I. Conditional neuronal simian virus 40 T antigen expression induces Alzheimer-like tau and amyloid pathology in mice. J Neurosci. 2007;27(11):2969-78. (Pubitemid 46438995)
25. Beal MF, Kowall NW, Ellison DW, Mazurek MF, Swartz KJ, Martin JB. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature. 1986;321:168-71. (Pubitemid 16022019)
26. Slow EJ, van Raamsdonk J, Rogers D, Coleman SH, Graham RK, Deng Y, et al. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum Mol Genet. 2003;12:1555-67. (Pubitemid 36857303)
27. Graham RK, Pouladi MA, Joshi P, Lu G, Deng Y, Wu N-P, et al. Differential susceptibility to excitotoxic stress in YAC128 mouse models of Huntington disease between initiation and progression of disease. J Neurosci. 2009;29(7):2193-204.
28. Schwarcz R, Guidetti P, Sathyasaikumar KV, Muchowski PJ. Of mice, rats, and men: revisiting the quinolinic acid hypothesis of Huntington's disease. Prog Neurobiol. 2010;90: 230-45.
29. Guidetti P, Bates GP, Graham RK, Hayden MR, Leavitt BR, MacDonald ME, et al. Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice. Neurobiol Dis. 2006;23:190-7. (Pubitemid 43922462)
30. Luo S, Vacher C, Davies JE, Rubinsztein DC. Cdk5 phosphorylation of huntingtin reduces its cleavage by caspases: Implication for mutant huntingtin toxicity. J Cell Biol. 2005;169(4):647-56. (Pubitemid 41002857)
31. Anne SL, Saudou F, Humbert S. Phopshorylation of huntingtin by cyclin-dependent kinase 5 is induced by DNA damage and regulates wild-type and mutant huntingtin toxicity in neurons. J Neurosci. 2007;27(27):7318-28. (Pubitemid 47037570)
32. Bae B-I, Xu H, Igarashi S, Fujimuro M, Agrawal N, Taya Y, et al. p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease. Neuron. 2005;47:29-41. (Pubitemid 40922848)
33. Lee J-H, Kim H-S, Lee S-J, Kim K-T. Stabilization and activation of p53 induced by cdk5 contributes to neuronal cell death. J Cell Sci. 2007;120(13):2259-71. (Pubitemid 47074130)